Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma

Current Oncology Reports

Volumn 11, Issue 5, 2009, Pages 363-370

  Alduaij, Waleed ^b   Illidge, Tim M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IODINE 131; MELPHALAN; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL TRIAL; DOSIMETRY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LUNG TOXICITY; LYMPHOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION ABSORPTION; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; RADIOIMMUNOTHERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 68949156444     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0049-8     Document Type: Review

References (42)

1. Green MR: Targeting targeted therapy. N Engl J Med 2004, 350:2191-2193.
2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
3. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
4. Schulz H, Bohlius JF, Trelle S, et al.: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706-714.
5. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984, 311:1471-1475.
6. Knox SJ, Meredith RF: Clinical radioimmunotherapy. Semin Radiat Oncol 2000, 10:73-93.
7. Illidge TM, Johnson PWM: The emerging role of radioimmunotherapy in haematological malignancies. Br J Haematol 2000, 108:679-688.
8. Deacon J, Peckham MJ, Steel GG: The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol 1984, 2:317-323.
9. Press OW: Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999, 5(Suppl 14):58-65.
10. Haas RLM, Poortmans P, de Jong D, et al.: High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003, 21:2474-2480.
11. Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996, 14:1282-1290.
12. Witzig TE, Flinn IW, Gordon LI, et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:3262-3269.
13. Witzig TE, White CA, Gordon LI, et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002, 20:2453-2463.
14. Kaminski MS, Zelenetz AD, Press OW, et al.: Pivotal study of iodine I 131 tositumomab for chemotherapyrefractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001, 19:3918-3928.
15. Horning SJ, Younes A, Jain V, et al.: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005, 23:712-719.
16. Emmanouilides C, Witzig TE, Gordon LI, et al.: Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006, 47:629-636.
17. Kaminski MS, Tuck M, Estes J, et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441-449.
18. Leonard JP, Coleman M, Kostakoglu L, et al.: Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005, 23:5696-5704.
19. Press OW, Unger JM, Braziel RM, et al.: A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003, 102:1606-1612.
20. Link B, Kaminski MS, Coleman M, Leonard JP: Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL) [abstract]. J Clin Oncol 2004, 22(14 Suppl):6520.
21. Morschhauser F, Radford J, Van Hoof A, et al.: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008, 26:5156-5164.
22. Gordon LI, Molina A, Witzig T, et al.: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004, 103:4429-4431.
23. Fisher RI, Kaminski MS, Wahl RL, et al.: Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005, 23:7565-7573.
24. Witzig TE, White CA, Wiseman GA, et al.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:3793-3803.
25. Witzig TE, White CA, Gordon LI, et al.: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003, 21:1263-1270.
26. Emmanouilides C, Witzig TE, Wiseman GA, et al.: Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2007, 22:684-691.
27. Morschhauser F, Illidge T, Huglo D, et al.: Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007, 110:54-58.
28. Younes A, Pro B, Rodriguez MA, et al.: Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract]. ASH Annual Meeting Abstracts 2005, 106:2452.
29. Liu SY, Eary JF, Petersdorf SH, et al.: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998, 16:3270-3278.
30. Press OW, Eary JF, Gooley T, et al.: A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000, 96:2934-2942.
31. Krishnan A, Nademanee A, Fung HC, et al.: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:90-95.
32. Winter JN, Inwards DJ, Spies S, et al.: Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009, 27: 1653-1659.
33. Shipley DL, Greco FA, Spigel DR, et al.: Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial [abstract]. J Clin Oncol 2005, 23(16 Suppl):6577.
34. Jacobs SA, Swerdlow SH, Kant J, et al.: Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008, 14:7088-7094.
35. Sharkey RM, Press OW, Goldenberg DM: A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: Prospects for dual-targeted antibody/radioantibody therapy. Blood 2009, 113:3891-3895.
36. Gopal AK, Press OW, Wilbur SM, et al.: Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008, 112:830-835.
37. Illidge TM, Bayne M, Brown NS, et al.: Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009, 113:1412-1421.
38. Tobinai K, Watanabe T, Ogura M, et al.: Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 2009, 100:158-164.
39. Jurczak W, Giza A, Szostek M, et al.: 90Y-Zevalin(R) (90Y-ibritumomab tiuxetan) radioimmunotherapy (RIT) consolidation of FCM induction chemotherapy in mantle cell lymphoma (MCL) patients: Results from the PLRG upon completed enrollment [abstract]. ASH Annual Meeting Abstracts 2006, 108:2747.
40. Smith MR, Chen H, Gordon L, et al.: Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499) [abstract]. J Clin Oncol (Meeting Abstracts) 2006, 24:7503.
41. van Oers MHJ, Klasa R, Marcus RE, et al.: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295-3301.
42. Hamlin PA, Moskowitz CH, Wegner BC, et al.: Early safety and efficacy analysis of a phase II study of sequential RCHOP and yttrium-90 ibritumomab tiuxetan (Zevalin) for elderly high risk patients with untreated DLBCL [abstract]. ASH Annual Meeting Abstracts 2005, 106:926.